NMR-Spectra-060-080

1H NMR spectra in raw Bruker format. Part 3 / 5

NMR-Spectra-105-125

1H NMR spectra in raw Bruker format. Part 5 / 5

NMR-Spectra-081-104

1H NMR spectra in raw Bruker format. Part 4 / 5

Metadata

Tabular data. Animal ID, intervention group, time under hypoxia, time to ROSC

Correlations between plasma and creatinine-normalized urine metabolite concentrations at all time points combined.

<p>Left margin shows dendrogram from hierarchical cluster analysis (HCA) by which rows and columns are ordered. Two major, separate clusters emerge for plasma (top right) and urine metabolites (bottom left), suggesting a low overall coherence between the two, and justifying treating the two independently in further analysis.</p

table_1_Anti-Inflammatory MicroRNAs and Their Potential for Inflammatory Diseases Treatment.DOCX

<p>Inflammation is a complicated biological and pathophysiological cascade of responses to infections and injuries, and inflammatory mechanisms are closely related to many diseases. The magnitude, the complicated network of pro- and anti-inflammatory factors, and the direction of the inflammatory response can impact on the development and progression of various disorders. The currently available treatment strategies often target the symptoms and not the causes of inflammatory disease and may often be ineffective. Since the onset and termination of inflammation are crucial to prevent tissue damage, a range of mechanisms has evolved in nature to regulate the process including negative and positive feedback loops. In this regard, microRNAs (miRNAs) have emerged as key gene regulators to control inflammation, and it is speculated that they are fine-tune signaling regulators to allow for proper resolution and prevent uncontrolled progress of inflammatory reactions. In this review, we discuss recent findings related to significant roles of miRNAs in immune regulation, especially the potential utility of these molecules as novel anti-inflammatory agents to treat inflammatory diseases. Furthermore, we discuss the possibilities of using miRNAs as drugs in the form of miRNA mimics or miRNA antagonists.</p

NMR-Spectra-002-035

1H NMR spectra in raw Bruker format. Part 1 / 5

Concentrations of urine metabolites at different time points, and individual, pairwise fold-change between them.

<p>Concentrations of urine metabolites at different time points, and individual, pairwise fold-change between them.</p

Parameters of the six included resuscitation protocols.

<p>Parameters of the six included resuscitation protocols.</p

Characteristics of the patients with a highest Pediatric Early Warning Score (PEWS) ≥3 compared to the patients with a highest PEWS of 0−2.

<p>p<0.05 is considered a significant difference (marked with *).</p